Literature DB >> 27284423

Prediction of outcome in breast cancer patients using test parameters from complete blood count.

Pingping Zhang1, Yulong Zong1, Mohan Liu2, Yanhong Tai3, Yuan Cao1, Chengiin Hu1.   

Abstract

The aim of this study was to evaluate the prognostic effect of test parameters from pretreatment complete blood count (CBC) for predicting outcome in breast cancer patients. A total of 162 patients with breast cancer and a long follow-up were enrolled in this study. Red cell indices (RCIs) and neutrophil-lymphocyte ratio (NLR) from CBC prior to treatment, as well as related clinical data, were retrospectively collected. We evaluated the association of RCI and NLR with tumor size, clinical stage, histological grade, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status. We further performed survival analysis and Cox multivariate analysis, stratified by RCI and NLR median values, to evaluate their prognostic effects. In the disease-free survival (DFS) analysis, patients in the higher mean corpuscular hemoglobin (MCH) and NLR groups exhibited shorter DFS times compared with those in the lower MCH and NLR groups (P=0.017 for MCH and P=0.039 for NLR). The univariate analysis revealed that both MCH and NLR were significantly associated with DFS. The Cox multivariate analysis demonstrated that only MCH was an independent predictor associated with disease relapse (hazard ratio = 1.975, 95% confidence interval: 1.118-3.487, P=0.019), whereas no index was associated with overall survival. Our results suggest that MCH prior to treatment may be a predictive marker associated with DFS in breast cancer.

Entities:  

Keywords:  breast cancer; mean corpuscular hemoglobin; neutrophil-to-lymphocyte ratio; prognosis; red cell indices

Year:  2016        PMID: 27284423      PMCID: PMC4887814          DOI: 10.3892/mco.2016.827

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  34 in total

1.  Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer.

Authors:  Oktay Bozkurt; Veli Berk; Muhammed Ali Kaplan; Bulent Cetin; Ersin Ozaslan; Halit Karaca; Mevlude Inanc; Ayse Ocak Duran; Metin Ozkan
Journal:  Asian Pac J Cancer Prev       Date:  2014

2.  Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer.

Authors:  Congwen Wei; Yuan Cao; Xiaoli Yang; Zirui Zheng; Kai Guan; Qiang Wang; Yanhong Tai; Yanhong Zhang; Shengli Ma; Ye Cao; Xiaoxing Ge; Changzhi Xu; Jia Li; Hui Yan; Youguo Ling; Ting Song; Lin Zhu; Buchang Zhang; Quanbin Xu; Chengjin Hu; Xiu-wu Bian; Xiang He; Hui Zhong
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-21       Impact factor: 11.205

3.  Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage.

Authors:  B C Blount; M M Mack; C M Wehr; J T MacGregor; R A Hiatt; G Wang; S N Wickramasinghe; R B Everson; B N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

4.  Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy.

Authors:  Mevlude Inanc; Ayse Ocak Duran; Halit Karaca; Veli Berk; Oktay Bozkurt; Ersin Ozaslan; Metin Ozkan
Journal:  Asian Pac J Cancer Prev       Date:  2014

5.  Prognostic impact of haemoglobin levels in breast cancer.

Authors:  Daniel Ulrich Boehm; Antje Lebrecht; Marcus Schmidt; Wulf Siggelkow; Christine Lindner; Antonia Litz; Eva Ulbrich; Heinz Koelbl
Journal:  Anticancer Res       Date:  2007 Mar-Apr       Impact factor: 2.480

Review 6.  Breast cancer in China.

Authors:  Lei Fan; Kathrin Strasser-Weippl; Jun-Jie Li; Jessica St Louis; Dianne M Finkelstein; Ke-Da Yu; Wan-Qing Chen; Zhi-Ming Shao; Paul E Goss
Journal:  Lancet Oncol       Date:  2014-06       Impact factor: 41.316

7.  Plasma folate, vitamin B-6, vitamin B-12, and risk of breast cancer in women.

Authors:  Jennifer Lin; I-Min Lee; Nancy R Cook; Jacob Selhub; JoAnn E Manson; Julie E Buring; Shumin M Zhang
Journal:  Am J Clin Nutr       Date:  2008-03       Impact factor: 7.045

8.  Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients.

Authors:  Hany Noh; Minseob Eomm; Airi Han
Journal:  J Breast Cancer       Date:  2013-03-31       Impact factor: 3.588

9.  Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia.

Authors:  H Ludwig; E Müldür; G Endler; W Hübl
Journal:  Ann Oncol       Date:  2013-04-07       Impact factor: 32.976

10.  Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer.

Authors:  A Bottini; A Berruti; M P Brizzi; A Bersiga; D Generali; G Allevi; S Aguggini; G Bolsi; S Bonardi; G Bertoli; P Alquati; L Dogliotti
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

View more
  9 in total

Review 1.  The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer.

Authors:  Anastasia Prodromidou; Panagiotis Andreakos; Charalampos Kazakos; Dimitrios Eftimios Vlachos; Despina Perrea; Vasilios Pergialiotis
Journal:  Inflamm Res       Date:  2017-03-04       Impact factor: 4.575

2.  Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade.

Authors:  Michele Moschetta; Mario Uccello; Benjamin Kasenda; Gabriel Mak; Anissa McClelland; Stergios Boussios; Martin Forster; Hendrik-Tobias Arkenau
Journal:  Biomed Res Int       Date:  2017-11-28       Impact factor: 3.411

3.  Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non-muscle-invasive bladder cancer patients.

Authors:  Bum Sik Tae; Jung Kwon Kim; Minyong Kang; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

4.  Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis.

Authors:  Xu Liu; Jing-Kun Qu; Jia Zhang; Yan Yan; Xi-Xi Zhao; Ji-Zhao Wang; Hang-Ying Qu; Lin Liu; Jian-Sheng Wang; Xiao-Yi Duan
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

5.  Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study.

Authors:  Stefanie Zorn; Janine Ehret; Rebecca Schäuble; Beate Rautenberg; Gabriele Ihorst; Hartmut Bertz; Paul Urbain; Anna Raynor
Journal:  BMC Cancer       Date:  2020-06-22       Impact factor: 4.430

6.  Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals.

Authors:  Wanying Guo; Xin Lu; Qipeng Liu; Ting Zhang; Peng Li; Weiqiang Qiao; Miao Deng
Journal:  Cancer Med       Date:  2019-06-13       Impact factor: 4.452

7.  Prognostic markers compared to CD3+TIL in locally advanced nasopharyngeal carcinoma.

Authors:  Nasser Al-Rajhi; Shamayel F Mohammed; Hatim A Khoja; Mohammad Al-Dehaim; Hazem Ghebeh
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

8.  Association between Oxidative Stress Parameters and Hematological Indices in Breast Cancer Patients.

Authors:  Hiva Danesh; Nasrin Ziamajidi; Seyed Alireza Mesbah-Namin; Nahid Nafisi; Roghayeh Abbasalipourkabir
Journal:  Int J Breast Cancer       Date:  2022-10-03

Review 9.  Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review.

Authors:  Iléana Corbeau; William Jacot; Séverine Guiu
Journal:  Cancers (Basel)       Date:  2020-04-13       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.